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Summary  The  main  cause  of  pulmonary  hypertension  in  newborn  babies  results  from  the
failure of  the  pulmonary  circulation  to  dilate  at  birth,  termed  ‘persistent  pulmonary  hyper-hypertension; tension of  the  newborn’  (PPHN).  This  syndrome  is  characterized  by  sustained  elevation  of
Newborn;
Inhaled  NO;
Hypoxaemia
pulmonary vascular  resistance,  causing  extrapulmonary  right-to-left  shunting  of  blood  across
the ductus  arteriosus  and  foramen  ovale  and  severe  hypoxaemia.  It  can  also  lead  to  life-
threatening circulatory  failure.  There  are  many  controversial  and  unresolved  issues  regarding
the pathophysiology  of  PPHN,  and  these  are  discussed.  PPHN  is  generally  associated  with  factors
Abbreviations: CDH, congenital diaphragmatic hernia; cGMP, cyclic guanosine monophosphate; ECMO, extracorporeal oxygenation;
eNOS, endothelial nitric oxide synthase; iNO, inhaled nitric oxide; NO, nitric oxide; NOS, nitric oxide synthase; PaCO2, partial pressure of
carbon dioxide in arterial blood; PO2, oxygen pressure; PPHN, persistent pulmonary hypertension of the newborn; PUFA, polyunsaturated
fatty acid; PVR, pulmonary vascular resistance; SpO2, saturation of peripheral oxygen; SSRI, selective serotonin reuptake inhibitor; VEGF,
vascular endothelial growth factor.
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such  as  congenital  diaphragmatic  hernia,  birth  asphyxia,  sepsis,  meconium  aspiration  and  respi-
ratory distress  syndrome.  However,  the  perinatal  environment—exposure  to  nicotine  and  certain
medications,  maternal  obesity  and  diabetes,  epigenetics,  painful  stimuli  and  birth  by  Caesarean
section—may  also  affect  the  maladaptation  of  the  lung  circulation  at  birth.  In  infants  with
PPHN, it  is  important  to  optimize  circulatory  function.  Suggested  management  strategies  for
PPHN include:  avoidance  of  environmental  factors  that  worsen  PPHN  (e.g.  noxious  stimuli,  lung
overdistension);  adequate  lung  recruitment  and  alveolar  ventilation;  inhaled  nitric  oxide  (or
sildenaﬁl, if  inhaled  nitric  oxide  is  not  available);  haemodynamic  assessment;  appropriate  ﬂuid
and cardiovascular  resuscitation  and  inotropic  and  vasoactive  agents.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  principale  cause  d’hypertension  pulmonaire  du  nouveau-né  résulte  d’une  vaso-
dilatation pulmonaire  insufﬁsante  à  la  naissance,  appelée  « hypertension  artérielle  pulmonaire
persistante  du  nouveau-né  » (HTAPP).  Ce  syndrome  est  caractérisé  par  une  élévation  des  résis-
tances vasculaires  pulmonaires,  responsable  d’un  shunt  droit-gauche  par  le  foramen  ovale
et le  canal  artériel  et  d’une  profonde  hypoxémie.  L’HTAPP  est  à  risque  vital  lorsque  qu’elle
s’accompagne  d’une  défaillance  circulatoire.  La  prise  en  charge  nécessite  un  recrutement  pul-
monaire adéquat,  l’inhalation  de  monoxyde  d’azote  et  un  support  cardiovasculaire  adapté.
Néanmoins,  la  physiopathologie  et  la  prise  en  charge  sont  toujours  l’objet  de  recherches  inno-
vantes. Ainsi,  de  plus  en  plus  d’arguments  existent  pour  penser  que  l’environnement  périnatal
joue un  rôle  déterminant  dans  la  genèse  et  l’aggravation  de  ce  syndrome.
.  Tous  droits  réservés.
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Figure 1. Schematic representation of the circulation in PPHN.
Sustained elevation of PVR contributes to low pulmonary blood ﬂow
and high pulmonary pressure, causing extrapulmonary right-to-left
shunting of blood across the ductus arteriosus and foramen ovale© 2013  Elsevier  Masson  SAS
ackground
ulmonary  hypertension  in  newborns  results  from  the  fail-
re  of  the  pulmonary  circulation  to  dilate  at  birth.  Termed
persistent  pulmonary  hypertension  of  the  newborn’  (PPHN),
t  occurs  in  an  estimated  1—2  infants  per  1000  live  births
1].  This  syndrome  is  characterized  by  sustained  elevation
f  pulmonary  vascular  resistance  (PVR),  causing  extrapul-
onary  right-to-left  shunting  of  blood  across  the  ductus
rteriosus  and  foramen  ovale  and  severe  hypoxaemia  [2,3]
Fig.  1).  PPHN  is  frequently  associated  with  low  systemic
ressure  and  low  cardiac  output  because  of  increased
ight  ventricular  afterload  and  myocardial  dysfunction  [2,4].
PHN-induced  circulatory  failure  is  a  life-threatening  condi-
ion.  Cardiac  failure  further  impairs  oxygen  delivery  to  the
issues  and  contributes  to  signiﬁcant  mortality  and  morbidity
n  newborn  infants  with  PPHN  [2—4].
Management  requires  adequate  lung  recruitment  and
lveolar  ventilation,  inhaled  nitric  oxide  (iNO),  and  appro-
riate  ﬂuid  and  cardiovascular  resuscitation  [5].  Early
nitiation  of  inotropic  and  vasoactive  agents  is  commonly
sed  to  increase  cardiac  output,  maintain  adequate  blood
ressure  and  enhance  oxygen  delivery  to  the  tissue  [4,6].
evertheless,  there  are  many  controversial  and  unresolved
ssues  regarding  the  pathophysiology  and  the  most  effective
anagement  of  PPHN.  Growing  evidence  is  emerging  that
ndicates  that  the  perinatal  environment  plays  a  key  role  in
his  syndrome.
athophysiologyoetal circulation
he  foetal  pulmonary  circulation  is  characterized  by  high
VR  and  low  blood  ﬂow.  Despite  high  pulmonary  artery
and severe hypoxaemia. LA: left atrium; LV: left ventricle; PPHN:
persistent pulmonary hypertension of the newborn; PV: pulmonary
vein; PVR: pulmonary vascular resistance; RA: right atrium; RV: right
ventricle.
pulmonary  hypertension  171
Figure 2. NO/cGMP pathway. NO, produced by endothelial NOS,
diffuses towards the smooth muscle cell in which it stimulates sol-
uble guanylate cyclase to produce cGMP. The mechanism whereby
increased cGMP regulates pulmonary vascular tone includes acti-
vation of K+ channels, causing smooth muscle cell membrane
hyperpolarization and inactivation of VOCC. Closure of VOCC causes
a decrease in cytosolic Ca++ concentration and vasorelaxation.
Intracellular concentration of cGMP is downregulated by PDE5 activ-
ities. Ca++: calcium; cGMP: cyclic guanosine monophosphate; eNOS:
endothelial nitric oxide synthase; GMP: guanosine monophosphate;
K+: potassium; NO: nitric oxide; NOS: nitric oxide synthase; PDE
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iImpact  of  the  perinatal  environment  on  newborn  persistent  
pressure,  the  lungs  are  perfused  with  less  than  10%  of
the  combined  ventricular  output  during  late  gestation  [7].
Owing  to  high  PVR  in  the  foetus,  most  of  the  right  ventricu-
lar  output  crosses  the  ductus  arteriosus  into  the  descending
aorta,  thereby  increasing  umbilical—placental  ﬂow  and  gas
exchange.
Mechanisms  that  maintain  high  PVR  in  utero  are  incom-
pletely  understood,  but  include  low  foetal  oxygen  pressure
(PO2)  [7],  lack  of  a  gas—liquid  interface  [8]  and  pro-
duction  of  vasoconstrictor  mediators  such  as  endothelin-1
[9].  Nitric  oxide  (NO)  production  also  modulates  foetal
pulmonary  vascular  tone  in  response  to  diverse  stimuli,
including  acute  changes  in  haemodynamic  forces  [8].  In
foetal  lambs,  acute  compression  of  the  ductus  arteriosus
abruptly  increases  blood  ﬂow  and  pressure,  and  causes  acute
pulmonary  vasodilation  through  the  shear  stress-induced
release  of  NO  [10—13]. However,  despite  maintenance  of
constant  pressure,  pulmonary  blood  ﬂow  progressively  falls
and  PVR  increases  over  time  [14,15].  Therefore,  the  foetal
pulmonary  circulation  is  characterized  by  an  ability  to
oppose  vasodilation  over  time  and  to  regulate  its  ﬂow.
Pulmonary adaptation at birth
At  birth,  pulmonary  blood  ﬂow  increases  dramatically,  by
8—10-fold,  and  PVR  drops  immediately.  Several  stimuli,
including  drainage  and  absorption  of  foetal  lung  liquid,
rhythmic  distension  of  the  lung,  increased  PO2 and  altered
production  of  several  vasoactive  products,  including  NO,
are  known  to  contribute  to  pulmonary  vasodilation  at  birth
[8].  The  effects  of  several  birth-related  stimuli,  including
increased  blood  ﬂow  or  shear  stress,  increased  PO2 and  ven-
tilation  are  partly  dependent  upon  activation  of  nitric  oxide
synthase  (NOS)  [8,10—13].
The  increase  in  NO  production  accounts  for  nearly  50%
of  the  abrupt  fall  in  PVR  at  birth  in  foetal  lambs  [8].  NO
mediates  vasodilatation  by  stimulating  soluble  guanylate
cyclase-induced  cyclic  guanosine  monophosphate  (cGMP)
production  [16]. cGMP  is  downregulated  by  phosphodieste-
rase  5  activity.  Phosphodiesterase  5,  which  is  abundantly
expressed  in  lung  tissue,  particularly  during  foetal  life,
is  a  key  regulator  of  perinatal  pulmonary  circulation  [17]
(Fig.  2).
Maladaptation of the pulmonary circulation at
birth
PPHN  is  a  clinical  syndrome  that  is  associated  with
diverse  neonatal  cardiopulmonary  diseases,  including  birth
asphyxia,  sepsis,  meconium  aspiration  and  respiratory  dis-
tress  syndrome,  or  it  can  be  idiopathic  [1—3].
The  usual  clinical  expression  of  PPHN  consists  of  an
unstable  refractory  hypoxaemia  with  pre-  and  postductal
saturation  of  peripheral  oxygen  (SpO2)  gradient.  Pulmonary
hypertension  can  be  associated  with  a  systemic  hypoten-
sion  and  symptoms  of  shock,  termed  ‘obstructive’  shock,
the  clinical  and  biological  signs  of  which  are  non-speciﬁc:
grey  colour,  tachycardia,  reﬁll  capillary  time  more  than
3  seconds,  oliguria,  systemic  hypotension  and  lactic  acido-
sis.  Doppler  echocardiography  is  required  to  determine  the
main  component  of  the  shock.  Management  priority  is  not  to
normalize  postductal  SpO2,  but  to  optimize  the  circulatory
p
p
d
o: phosphodiesterase 5; SMC: smooth muscle cell; VOCC: voltage-
perated calcium channels.
unction.  A  rigorous  clinical  and  echocardiographic  assess-
ent  is  required  for  early  diagnosis  of  circulatory  failure.
ore  relevant  than  changes  in  postductal  SpO2,  reﬂecting
ight-to-left  ductus  arteriosus  shunting,  the  decrease  in  pre-
uctal  SpO2 results  from  an  increase  in  the  right-to-left
hunting  through  the  foramen  ovale.  It  occurs  when  the
ulmonary  venous  return  decreases  (which  reduces  the  left
trial  pressure)  or  in  case  of  right  cardiac  failure  (leading
o  elevation  of  right  atrial  pressure).  Both  are  markers  for
otential  circulatory  failure.  In  most  cases,  low  postductal
pO2 alone  (i.e.  with  normal  preductal  SpO2)  does  not  cause
issue  hypoxia.  In  contrast,  a  drop  in  preductal  SpO2 is  usu-
lly  associated  with  symptoms  of  shock  and  an  increased
actate  concentration.
Experimental  studies  of  chronic  pulmonary  hypertension
n  newborn  animals  have  demonstrated  impaired  endothelial
elease  of  NO  and  increased  production  of  vasoconstric-
ors  (e.g.  endothelin-1)  [18]. In  normal  foetal  lambs,  acute
ompression  of  the  ductus  arteriosus  causes  progressive
ulmonary  vasodilation,  which  is  blocked  by  NOS  inhibi-
ion,  suggesting  that  NO  mediates  shear  stress-induced
asodilation.  After  NOS  inhibition,  acute  ductus  arterio-
us  compression  causes  a  marked  pulmonary  vasoconstrictor
esponse,  suggesting  that  NOS  blockade  unmasks  a  potent
yogenic  response  in  the  normal  foetal  lung  [14]. In  con-
rast,  exposure  to  chronic  pulmonary  hypertension  for  2  days
mpairs  ﬂow-induced  vasodilation  and  enhances  the  myo-
enic  response  during  acute  ductus  arteriosus  compression
n  the  absence  of  NOS  inhibition  [19,20]. Therefore,  with
rolonged  pulmonary  hypertension  during  the  perinatal
eriod,  pulmonary  blood  ﬂow  is  autoregulated  and  indepen-
ent  of  pulmonary  artery  pressure.  The  most  striking  feature
f  perinatal  pulmonary  hypertension  is  the  loss  of  the  normal
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asodilator  response  to  birth-related  stimuli  causing  a  para-
oxical  vasoconstriction  to  acute  haemodynamic  stress.
Several  investigators  have  suggested  that  an  increase
n  PDE5  activity  may  contribute  to  this  phenomenon.  Lung
DE5  activity  increased  by  150%  in  foetal  lambs  with
uctus  arteriosus  ligation  for  8  days  compared  to  control
ambs  [21]. Sildenaﬁl  attenuates  the  progressive  eleva-
ion  of  basal  pulmonary  vascular  tone  observed  during
hronic  pulmonary  hypertension,  and  preserves,  at  least
n  part,  the  physiological  pulmonary  vascular  response  to
asodilators  [22].
More  recently,  the  role  of  vascular  endothelial  growth
actor  (VEGF)  in  foetal  lung  development  and  the  patho-
enesis  of  PPHN  have  been  reported.  VEGF  is  a  potent
ndothelial  cell  mitogen  and  regulator  of  angiogenesis.
n  vivo  inhibition  of  VEGF  receptors  in  normal  foetal
heep  results  in  impaired  vascular  growth  and  pul-
onary  hypertension  [23]. Impaired  alveolarization  and
essel  growth  in  chronic  intrauterine  pulmonary  hyper-
ension  are  associated  with  decreased  VEGF  protein
xpression  [24].
isk factors for PPHN: impact of the
nvironment
PHN  is  usually  associated  with  pulmonary  parenchymal  dis-
ase,  such  as  meconium  aspiration,  pneumonia  or  hyaline
embrane  disease;  or  with  disease-related  lung  hypoplasia
ncluding  congenital  diaphragmatic  hernia  (CDH)  or  prema-
ure  rupture  of  the  membrane-mediated  oligohydramnios
1—3].  However,  growing  evidence  indicates  that  the  foetal
nvironment  plays  a  critical  role  in  the  maladaptation  of  the
ung  circulation  at  birth.  Evidence  of  a  role  for  epigenetics  in
he  development  of  pulmonary  arterial  hypertension  is  also
merging.  Epigenetic  mechanisms  are  involved  in  the  reg-
lation  of  gene  expression,  which  are  controlled,  at  least
n  part,  by  environment.  In  newborn  rats  with  pulmonary
ypertension,  the  increased  expression  of  endothelial  NOS  is
ssociated  with  changes  in  epigenetic  regulation  [25]. In  the
ame  way,  pulmonary  hypertension  has  been  associated  with
bnormal  epigenetic  regulation  of  superoxide  dismutase  and
ypoxia  inducible  factor  [26].
ntenatal smoke exposure
otinine  concentrations  in  cord  blood  —  a  biological  marker
or  nicotine  exposure  — have  been  found  to  be  higher  in
nfants  with  PPHN  than  in  healthy  control  newborn  infants
27].  Prenatal  cigarette  smoke  has  been  found  to  increase
he  risk  of  PPHN  among  premature  infants  less  than  30  weeks
estational  age,  suggesting  a  toxic  effect  on  the  pulmonary
ascular  development  and  maturation  [28]. Studies  of  lungs
xposed  in  utero  to  cigarette  smoke  have  shown  marked
tructural  and  functional  changes,  such  as  decreased  alve-
lar  attachments  to  the  airway  wall  and  increased  airways
esponsiveness.  Endothelial  dysfunction  in  intrapulmonary
rteries  has  been  found  during  exposure  to  tobacco  smoke
ontributing,  at  least  in  part,  to  vasoconstriction  and  smooth
uscle  cell  proliferation  [29]. In  an  experimental  model  of
oetal  lambs,  we  found  that  prenatal  exposure  to  cigarette
o
s
dL.  Storme  et  al.
moke  causes  a potent  and  sustained  pulmonary  vasocon-
triction  in  the  foetus,  and  blunts  the  vasodilator  response
o  an  increase  in  oxygen  tension  [30]. These  effects  are
ssociated  with  a  marked  decrease  in  foetal  oxygenation.
s  the  postnatal  circulatory  adaptation  is  highly  dependent
n  the  decrease  in  PVR  and  the  vasodilator  response  to
irth-related  stimuli,  such  as  oxygen,  we  speculate  that  pre-
atal  exposure  to  tobacco  smoke  increases  the  risk  of  PPHN
hrough  failure  of  the  pulmonary  circulation  to  dilate  at
irth.
ole of stress or pain
orticosteroids  and  catecholamine  are  the  main  stress  hor-
ones.  Their  effects  on  lung  parenchyma  maturation,  lung
uid  clearance  and  surfactant  release  at  birth  have  been
idely  investigated.  Evidence  has  emerged  that  the  stress
ormones  promote  normal  circulatory  adaptation  at  birth.
everal  experimental  and  clinical  studies  have  shown  that
orepinephrine  improves  circulation  in  the  perinatal  lung.
n  foetal  lambs,  norepinephrine  has  been  shown  to  increase
ung  blood  ﬂow  and  reduce  PVR  [31]. Norepinephrine  induces
n  NO-dependent  pulmonary  vasodilation  in  the  ovine  foetus
hrough  activation  of  2-adrenoceptors  [32—35]. In  a  large
etrospective  review  of  nearly  30,000  consecutive  deliver-
es  over  7  years,  the  incidence  of  PPHN  in  newborn  infants
elivered  by  elective  Caesarean  was  almost  ﬁve  times  higher
han  among  those  delivered  vaginally  [36]. A  likely  hypoth-
sis  for  PPHN  after  Caesarean  is  that  there  might  be  an
dvantage  to  labour  and  vaginal  delivery  for  the  pulmonary
ascular  bed  of  the  neonate.  Mechanisms  explaining  the
ncrease  in  PPHN  after  Caesarean  remain  unclear.  A  surge
f  catecholamines,  especially  norepinephrine,  is  observed
t  birth.  However,  neonatal  norepinephrine  concentrations
re  signiﬁcantly  lower  after  Caesarean  section  than  after
aginal  delivery.  Lower  levels  of  circulating  norepinephrine
fter  Caesarean  section  may  explain,  at  least  in  part,  the
igh  incidence  of  PPHN  in  newborn  infants  delivered  by  Cae-
arean  section  [37].
In contrast,  evidence  exists  that  painful  stimuli  impair
ormal  adaptation  at  birth  and  promote  PPHN.  Hypox-
emia  is  usually  observed  during  stressful  intensive  care
rocedures  in  newborn  infants  with  respiratory  failure,
he  duration  of  which  may  be  reduced  by  opioid  anal-
esia  [38]. In  foetal  lambs,  nociceptive  stimuli  increase
ulmonary  artery  pressure  and  PVR  [39,40]. This  vaso-
onstrictive  response  is  abolished  by  analgesia  and  by
1-adrenoceptor  blockade  [41]. These  results  provide  new
nsights  into  the  mechanisms  by  which  stressful  events  may
orsen  hypoxaemia  in  newborn  infants  with  PPHN.  Noci-
eptive  stimulation,  through  1-adrenoceptor  activation,
ay  elevate  pulmonary  vascular  tone  leading  to  increased
ight-to-left  shunting  through  the  ductus  arteriosus  and  the
oramen  ovale  and  to  severe  hypoxaemia.
rug exposure
rug  administration  during  pregnancy  may  increase  the  risk
f  maladaptation  at  birth.
The  likelihood  of  PPHN  increases  after  antenatal  expo-
ure  to  aspirin  or  other  non-steroidal  anti-inﬂammatory
rugs  [42]. Mechanisms  of  antenatal  non-steroidal
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anti-inﬂammatory-induced  PPHN  may  include  antena-
tal  closure  of  the  ductus  arteriosus  or  decreased  production
of  vasodilator  prostaglandins.  Similar  risks  exist  after  birth:
ibuprofen  administration  has  the  potential  to  cause  PPHN
in  preterm  infants  with  patent  ductus  arteriosus  [43].
Selective  serotonin  reuptake  inhibitors  (SSRIs),  used  to
treat  maternal  depression,  elevate  the  basal  vascular  tone
in  the  foetal  lung  [44]. Pulmonary  vascular  remodelling  and
right  ventricular  hypertrophy  have  been  observed  in  rat  pups
after  maternal  exposure  to  ﬂuoxetine  [45]. A  case-control
study  to  assess  whether  PPHN  is  associated  with  exposure  to
SSRIs  has  been  conducted  during  late  pregnancy  [46]. A  total
of  377  women  whose  infants  had  PPHN  and  836  matched  con-
trol  women  were  enrolled  in  the  study.  Fourteen  infants  with
PPHN  had  been  exposed  to  antenatal  SSRI,  as  compared  with
six  control  infants  (adjusted  odds  ratio  6.1,  95%  conﬁdence
interval  2.2—16.8)  [46]. These  data  support  an  association
between  the  maternal  use  of  SSRIs  in  late  pregnancy  and
PPHN  in  the  offspring.
In  case  of  severe  respiratory  failure,  early  initiation  of
inotropic  and  vasoactive  agents  is  warranted  to  increase
cardiac  output,  maintain  adequate  blood  pressure  and
enhance  oxygen  delivery  to  the  tissue  [47]. Dopamine  is
the  sympathomimetic  amine  most  frequently  used  for  sep-
tic  shock  in  newborn  infants.  The  ability  of  dopamine  to
raise  systemic  blood  pressure  has  been  clearly  documented.
However,  dopamine  has  also  been  suggested  to  increase
pulmonary  artery  pressure  and  pulmonary/systemic  mean
arterial  pressure  ratio  in  experimental  models  and  in  human
[31,48].  Caution  should  therefore  be  advocated  in  the  use
of  dopamine  in  newborn  infants  at  risk  of,  or  with,  PPHN.
Perinatal nutrition
It  has  been  well  established  that  maternal  obesity  and
diabetes  are  associated  with  increased  risks  of  maladapta-
tion  at  birth  [49]. The  exact  mechanisms  are  unclear,  but
include  perinatal  asphyxia,  parenchymal  disease  and  poly-
cythaemia.  Studies  have  highlighted  that  infants  with  PPHN
are  deﬁcient  in  the  amino  acid,  L-arginine,  which  is  required
for  NO  synthesis  [50]. Evidence  exists  that  differential  vas-
cular  effects  can  be  expected  according  to  lipid  intake.
Indeed,  dietary  ﬁsh  oils  have  beneﬁcial  effects  on  cardiac
and  vascular  function,  including  effects  on  platelet/vessel
wall  interactions,  endothelial  function  and  inhibition  of
smooth  muscle  cell  proliferation.  The  n3  polyunsaturated
fatty  acids  (PUFAs)  are  metabolized  by  several  enzymes,
including  cyclooxygenase,  to  produce  prostaglandins  (PGE3,
PGI3),  which  are  known  potential  vasodilator  mediators.  In
addition,  n3  PUFA  competes  with  arachidonic  acid  (n6  PUFA)
for  enzymatic  conversion.  This  competition  decreases  for-
mation  of  vasoactive  arachidonic  acid  metabolites  such  as
thromboxane  A2,  a  potent  pulmonary  vasoconstrictor.  Thus,
some  evidence  suggests  that  n3  PUFA  may  be  beneﬁcial  in
conditions  associated  with  pulmonary  hypertension.  Also,  n3
PUFA  induces  a  potent  pulmonary  vasodilatation  in  the  peri-
natal  lung  [51]. This  effect  is  abolished  by  cytochrome  450
epoxygenase,  but  not  by  NOS  inhibitors.  Our  data  provide
evidence  for  potential  beneﬁcial  effects  of  n3  PUFA  on  the
pulmonary  circulation  through  production  of  epoxides.  n3
PUFA  supplementation  may  help  to  prevent  maladaptation
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t birth,  in  particular  in  conditions  with  prolonged  pul-
onary  hypertension  such  as  CDH  or  pulmonary  hypoplasia.
xygen and hyperoxia
hile  oxygen  stimulates  endothelial  nitric  oxide  synthase
eNOS)  and  NO  production  and  contributes  to  pulmonary
daptation  at  birth  [8],  high  concentrations  of  oxygen,
uch  as  are  used  to  treat  PPHN,  may  produce  reactive
xygen  species.  For  instance,  hydrogen  peroxide  (H2O2)
ould  decrease  eNOS  promoter  activity,  associated  with
n  endothelin-1-mediated  downregulation  of  eNOS  expres-
ion  [52]. Uncoupled  eNOS  has  been  shown  to  increase
uperoxide  radicals,  which  rapidly  combine  with  NO  to
orm  peroxynitrite,  a  potent  pulmonary  vasoconstrictor
nd  potential  cellular  toxin.  Furthermore,  hyperoxia  may
lunt  NO-mediated  pulmonary  vasodilation  through  increas-
ng  phosphodiesterase  5  activity.  In  accordance  with  these
tudies,  recombinant  human  superoxide  dismutase  enhances
asodilation  after  birth  in  experimental  models  of  PPHN
53].
rinciples of management
asic principles
n  PPHN  with  right-to-left  shunt  through  the  ductus  arterio-
us,  the  contribution  of  hypoxaemia  to  tissue  oxygenation
low  partial  pressure  of  oxygen  in  arterial  blood  [PaO2])  is
ikely  to  be  modest,  provided  SpO2 in  the  preductal  area
s  greater  than  80%,  circulatory  function  is  adequate  and
aemoglobin  concentration  is  normal.  Similarly,  hypoxaemia
uring  foetal  life  (SpO2 60—75%)  or  during  cyanotic  congen-
tal  heart  diseases  is  not  associated  with  tissue  hypoxia,
s  long  as  cardiac  function  is  normal.  However,  there  is
ome  evidence  to  suggest  that  cardiac  dysfunction  may
lay  a  major  role  in  PPHN.  Severe  pulmonary  hyperten-
ion  increases  right  ventricular  afterload  that  may  result
n  right  ventricular  failure.  The  resulting  elevation  of  right
entricular  telediastolic  pressure  causes  right-to-left  shunt-
ng  through  the  foramen  ovale  and  worsens  hypoxaemia.
ecause  of  a  high  degree  of  interdependence  between  the
ight  and  the  left  ventricles  due  to  the  presence  of  common
tructures  (the  interventricular  septum  and  the  inextensible
ericardium),  changes  in  the  right  ventricle  size  and  geome-
ry  may  alter  the  left  ventricular  function.  This  may  explain
hy  PPHN  is  usually  associated  with  low  systemic  pressure
nd  low  cardiac  output  requiring  the  use  of  cardiac  sup-
ort  [2—4]. Right  ventricle  failure  occurs  when  the  ductus
rteriosus  is  closed  or  restricted.  In  severe  PPHN  with  right-
o-left  shunting  through  the  ductus  arteriosus,  both  the  left
nd  right  ventricle  contribute  to  systemic  blood  ﬂow  (Fig.  3).
herefore,  management  of  the  newborn  infant  with  PPHN
equires  both  lowering  of  PVR  and  support  of  cardiovascular
unction  (Table  1).
nvironmental factorsirst,  exposure  to  environmental  factors  that  worsen  PPHN
hould  be  avoided.  Noxious  stimuli,  including  tactile  stimuli,
racheal  suction  and  heel  pricks  have  to  be  limited  as  much
174  L.  Storme  et  al.
Figure 3. Schematic representation of the circulation in PPHN. Because of elevated PVR, part of the right ventricular outﬂow is directed
towards the systemic circulation through the ductus arteriosus, contributing to systemic blood ﬂow. Despite a right-to-left ductus arteriosus
shunting-mediating drop in postductal SpO2, oxygen supply is usually adequate as long as the ductus arteriosus is widely patent. Both aortic
and pulmonary artery pressures are closely related when the ductus arteriosus is patent (low ductal resistance). Thus, aortic pressure plays
a critical role in pulmonary circulation. A drop in aortic pressure is associated with a decrease in pulmonary artery pressure, and since
pulmonary artery pressure is the driving force for lung blood ﬂow, a decrease in aortic pressure-induced drop in pulmonary artery pressure
may worsen hypoxaemia and oxygen delivery. This electrical representation further highlights that a patent ductus arteriosus and normal
right ventricle function are required for sustaining systemic blood ﬂow and oxygen supply. F(PAP): proportional to pulmonary artery pressure;
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pA: pulmonary artery; PAP: pulmonary artery pressure; PPHN: persi
esistance; SVR: systemic vascular resistance.
s  possible.  A  speciﬁc  pain  scale  for  newborns  should  be
sed  to  titrate  analgesia  and  optimize  their  environment
reduce  noise  and  light,  ‘cocooning’).  Overdistension  of  the
ungs  contributes  to  a  decrease  in  pulmonary  blood  ﬂow  and
hould  be  prevented,  in  particular  in  conditions  associated
ith  pulmonary  hypoplasia  (CDH  and  premature  rupture  of
he  membranes).  Polycythaemia-mediating  increased  blood
iscosity  and  increased  pulmonary  artery  pressure  should  be
orrected.
echanical ventilation
anagement  requires  adequate  lung  recruitment  and
lveolar  ventilation,  appropriate  ﬂuid  and  cardiovascular
esuscitation  and  use  of  pulmonary  vasodilators  [5].  In
DH,  mask  ventilation  should  be  avoided  during  resus-
itation  in  the  delivery  room  to  prevent  gut  distension
ocated  in  the  thoracic  cavity.  High  airway  pressures  should
lso  be  avoided,  to  prevent  pulmonary  barotraumas  while
a
m
i
o pulmonary hypertension of the newborn; PVR: pulmonary vascular
aintaining  preductal  oxygen  saturation  greater  than  85%
nd  partial  pressure  of  carbon  dioxide  in  arterial  blood
PaCO2)  of  40—55  mmHg.  Centres  with  better-than-expected
DH  survival  report  the  combination  of  establishing  clini-
al  care  guidelines  that  set  limits  on  ventilatory  pressures
o  avoid  lung  overdistension  and  accepting  adequate  blood
as  rather  than  optimal  PaCO2 and  PaO2,  as  long  as
here  is  evidence  of  adequate  cardiac  output  and  organ
unction  [54].
Infants  with  signiﬁcant  right-to-left  shunting  require  pul-
onary  vasodilator  therapy.  Currently,  iNO  is  recommended
or  infants  with  PPHN  [55]. This  improves  outcomes  in  hypox-
emic  term  and  near-term  infants  by  reducing  the  incidence
f  the  combined  endpoint  of  death  or  need  for  extracor-
oreal  oxygenation  (ECMO)  [55]. Oxygenation  improves  in
pproximately  50%  of  infants  receiving  iNO  [55]. Improve-
ent  in  oxygenation  has  also  been  reported  with  the  use  of
NO  in  newborns  with  CDH  and  PPHN  [56]. However,  early  use
f  iNO  does  not  appear  to  improve  the  combined  endpoint  of
Impact  of  the  perinatal  environment  on  newborn  persistent  pulm
Table  1  Steps  in  the  management  of  PPHN.
Step  Action
1  Prevent  exposure  to  environmental  factors  that
may  worsen  PPHN  (e.g.  stress,  painful  stimuli,
noise,  excessive  light,  lung  overdistension)
2  Provide  adequate  lung  expansion  and  ventilation
3 Provide  inhaled  nitric  oxide
4 Assess  for  haemodynamics  (clinical  examination,
chest  X-ray,  cardiothoracic  index,  Doppler
echocardiography)
5  Provide  appropriate  ﬂuid  expansion  and
vasoactive  support  according  to  the  main
component  of  the  circulatory  failure
(obstructive,  hypovolaemic,  distributive  or
cardiogenic)
6  ECMO  may  be  required  in  life-threatening
obstructive  shock
ECMO: extracorporeal oxygenation; PPHN: persistent pulmonary
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death/ECMO  in  infants  with  CDH  alone  [57]. Usual  concen-
trations  of  iNO  for  the  treatment  of  PPHN  are  5—20  ppm.
Supporting cardiovascular function
Early  initiation  of  inotropic  and  vasoactive  agents  is  warr-
anted  to  increase  cardiac  output,  maintain  adequate  blood
pressure  and  enhance  oxygen  delivery  to  the  tissues.
Systemic  hypotension  is  usually  poorly  tolerated,  with
worsening  of  hypoxia  explained  by:
• a  decrease  in  left  ventricle  ﬁlling  causing  a  decrease  in
oxygen  delivery  to  the  tissue;
• a  decrease  in  coronary  ﬂow;
• a  drop  in  pulmonary  pressure  resulting  in  a  decrease  in
pulmonary  blood  ﬂow.
Indeed,  as  the  ductus  arteriosus  is  usually  patent  in
newborns  with  PPHN,  pulmonary  artery  pressure  and  aortic
pressure  are  closely  related  (Fig.  3).  A  decrease  in  systemic
pressure-mediated  drop  in  pulmonary  artery  pressure  causes
a  decrease  in  pulmonary  blood  ﬂow,  as  Flow  =  f(Pressure).
Therefore,  careful  assessment  of  haemodynamics  (clini-
cal  examination,  chest  X-ray,  cardiothoracic  index  and
echocardiography)  is  required  in  PPHN  to  provide  optimal
treatment.
Four  types  of  shock,  according  to  the  main  mechanism
responsible  for  the  cardiocirculatory  failure,  can  be  distin-
guished  in  the  newborn:
• hypovolaemic;
• vasoplegic;
• cardiogenic;
• obstructive.
Fluid  resuscitation  should  only  be  used  if  there  is  evi-
dence  for  hypovolaemia.  Cardiogenic  shock  —  a  rare  event
in  PPHN  as  long  as  the  ductus  arteriosus  is  widely  patent  —
may  require  inotropic  drug  infusion  (dobutamine).  The  use
of  vasoactive  drug  is  usually  warranted  in  vasoplegic  or
obstructive  shock.
C
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CMO
CMO  may  be  required  to  ensure  effective  oxygenation  and
ecarboxylation,  to  limit  the  baro-volotrauma  of  the  lungs
nd  to  improve  right  cardiac  failure.  ECMO  is  indicated  when
ypoxaemia  persists  despite  optimal  medical  management.
CMO  may  be  indicated  based  on  the  following  criteria  [1]:
preductal  SpO2 less  than  80%  despite  peak  inspiratory
pressure  greater  than  28  cmH2O  (or  mean  airway  pres-
sure  greater  than  15  cmH2O  in  high  frequency  oscillatory
ventilation);
PPHN  and  circulatory  failure  resistant  to  adequate  man-
agement;
gestational  age  greater  than  34  weeks;
birth  weight  greater  than  2  kg.
ulmonary vasodilator drugs
here  is  limited  experience  in  PPHN  with  other  pharmaco-
ogical  pulmonary  vasodilators.
Phosphodiesterase  inhibitors  reduce  the  degradation  of
GMP  produced  by  endogenous  or  inhaled  NO.  Sildenaﬁl  has
een  found  to  improve  cardiac  output  and  respiratory  func-
ion  by  reducing  pulmonary  hypertension  refractory  to  iNO  in
even  newborns  with  CDH  [58]. In  chronic  pulmonary  hyper-
ension  associated  with  CDH,  sildenaﬁl  has  been  found  to
mprove  pulmonary  vascular  function  and  promoted  lung
rowth  [59]. Evidence  exists  that  sildenaﬁl  is  well  tolerated
n  the  newborn  infant  with  PPHN  [60]. A  meta-analysis  of
hree  trials  including  77  newborn  infants  with  PPHN  has  indi-
ated  that  sildenaﬁl  may  improve  oxygenation  and  reduce
ortality  [61]. The  studies  were  performed  in  resource-
imited  settings  where  iNO  was  not  available.  The  results  of
he  meta-analysis  suggest  that  sildenaﬁl  in  the  treatment
f  PPHN  has  signiﬁcant  potential,  especially  in  resource-
imited  settings.
The  use  of  prostacyclin  and  analogues  is  an  established
herapy  for  children  and  adults  with  primary  pulmonary
ypertension.  In  a  recent  population-based  study,  the  use  of
rostacyclin,  along  with  various  other  measures,  has  been
ssociated  with  a  high  survival  rate  [62]. Subcutaneous  tre-
rostinil  has  been  found  to  improve  functional  symptoms  in
oung  children  with  refractory  pulmonary  arterial  hyperten-
ion  [63]. However,  its  use  in  PPHN  has  not  been  reported.
Similarly,  there  is  evidence  to  suggest  that  endothe-
in  receptor  blockade  may  improve  pulmonary  blood  ﬂow
n  PPHN.  In  an  experimental  model  of  foetal  pulmonary
ypertension,  intrauterine  endothelin  receptor  blockade
ecreased  pulmonary  artery  pressure,  decreased  right  ven-
ricular  hypertrophy  and  distal  muscularization  of  small
ulmonary  arteries  and  increased  the  fall  in  PVR  at  deliv-
ry  [64]. Bosentan  is  a  non-speciﬁc  endothelin-1  receptor
nhibitor  that  improves  pulmonary  hypertension  in  adult
atients.  Although  recent  reports  suggest  that  bosentan  may
mprove  PPHN  [65], there  is  still  insufﬁcient  evidence  to
upport  the  use  of  bosentan  in  the  management  of  PPHN.onclusions
rowing  evidence  indicates  that  the  perinatal  environment
lays  a  key  role  in  the  failure  of  cardiopulmonary  transition
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[76  
o  adequate  pulmonary  circulation  at  birth.  Reduction  of
xposure  to  risk  factors  should  be  the  ﬁrst  step  in  the  pre-
ention  of  PPHN.  New  insights  showing  that  PPHN  may  be
ssociated  with  epigenetic  modiﬁcations  suggest  that  novel
harmacological  interventions  targeting  modulation  of  epi-
enetic  regulation  may  be  beneﬁcial.
PPHN  causes  hypoxaemia  through  extrapulmonary  right-
o-left  shunting.  The  management  priority  should  be  to
ptimize  circulatory  function  rather  than  normalize  post-
uctal  SpO2,  because  PPHN-induced  circulatory  failure  is  a
ife-threatening  condition.
Management  of  PPHN  requires  adequate  lung  recruit-
ent  and  alveolar  ventilation,  iNO  and  appropriate  ﬂuid
nd  cardiovascular  resuscitation.  Early  initiation  of  inotropic
nd  vasoactive  agents  is  commonly  used  to  increase  car-
iac  output,  maintain  adequate  blood  pressure  and  enhance
xygen  delivery  to  the  tissue.  However,  a  rigorous  clinical
nd  echocardiographic  assessment  is  required  for  optimal
anagement  of  PPHN-associated  circulatory  failure.
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